Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
Lung Cancer: Targets and Therapy · 2021-07 · Volume 12 · 61-65
DOI: 10.2147/lctt.s307321 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Lung Cancer: Targets and Therapy, 2021-07. Verfasst von Shannon S Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Irvine School of Medicine, Department of Medicine, Orange, CA, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
The EGFR exon 20 insertion (EGFRex20ins) mutations are the third most common EGFR mutations seen in non-small cell lung cancer (NSCLC). More than 50 variants of EGFRex20ins mutations have been identified with A767_V769dupASV being the most common variant across multiple surveys. Treatment with currently available EGFR tyrosine kinase inhibitors (TKIs) including osimertinib is generally ineffective. Amivantamab (JNJ-372), a bispecific monoclonal antibody against EGFR and MET, has recently been approved by the US FDA for patients with advanced or metastatic NSCLC harboring EGFRex20ins mutations after disease progression on platinum-based chemotherapy. Among all the TKIs in clinical development, mobocertinib (TAK-788) has been granted priority review by the FDA for the same indication as amivantamab. Here, we provide a concise review on mobocertinib, with a focus on its chemical structure, preclinical data, and phase 1/2 trial results. Future directions will likely focus on combination approach such as TKI plus chemotherapy in the first-line setting, designing drugs with CNS activity, and exploring disease characteristics of various EGFRex20ins mutation variants and how they may affect treatment response.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of California, Irvine School of Medicine, Department of Medicine, Orange, CA, USA.
- Chao Family Comprehensive Cancer Center, Orange, CA, USA.
Zitieren
APA
Zhang, S. S., & Zhu, V. W. (2021). Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations. Lung Cancer: Targets and Therapy, Volume 12, 61-65. https://doi.org/10.2147/lctt.s307321
Vancouver
Zhang SS, Zhu VW. Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations. Lung Cancer: Targets and Therapy. 2021;Volume 12:61-65. doi:10.2147/lctt.s307321
BibTeX
@article{Zhang2021,
author = {Zhang, Shannon S and Zhu, Viola W},
title = {Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations},
journal = {Lung Cancer: Targets and Therapy},
year = {2021},
volume = {Volume 12},
pages = {61--65},
doi = {10.2147/lctt.s307321}
}
EUVIMED